Rabies Vaccine Adverse Reaction Clinical Trial
Official title:
Safety of Rabivax-S in Individuals Receiving Pre-exposure Prophylaxis (PrEP)
People who are at frequent or continuous risk of exposure to rabies virus should be vaccinated against the disease (pre-exposure prophylaxis). This includes people who work with rabies virus in research or diagnostic laboratories or vaccine production facilities, veterinarians, staff, animal-control and wildlife workers in areas where rabies is endemic. Veterinary students in clinical placements and externships are included in this category. Currently, DVM students at Ross University School of Veterinary Medicine (RUSVM) are vaccinated against rabies in their 7th semester (final pre-clinical semester). Vaccinations are done by RUSVM Health Services using Rabivax-S, produced by the Serum Institute of India (study co-sponsors). Previously-unvaccinated students receive three injections of vaccine, on day 0, 7 and 21-28. The aim of the study is to generate additional data on safety and tolerability of Rabivax-S administered as pre-exposure prophylaxis to this population.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06078423 -
A Clinical Trial of Freeze-dried Human Rabies Vaccine (MRC-5 Cells)
|
Phase 3 | |
| Active, not recruiting |
NCT04852068 -
A Clinical Trial of Freeze-dried Human Rabies Vaccine (Vero Cells)
|
Phase 3 |